High-Dose Imatinib for Relapsed/Refractory c-Kit Positive Acute Myelogenous Leukemia (AML)
Status:
Completed
Trial end date:
2009-01-01
Target enrollment:
Participant gender:
Summary
This is a multicenter open-label phase II trial of high dose imatinib mesylate in patients
with AML in first or second relapse, or with refractory disease. Daily dosing of imatinib 600
mg/day is planned for one month or until progression of disease. Dose increase to 800 mg/ day
imatinib is permitted for 2 additional months in the event of response failure. Response is
assessed after 1, 2 and 3 months of treatment by bone marrow aspirate.